Date: September 26, 2023
Your Name: Nao Wakasugi-Sato
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 2023
Your Name: Tatsurou Tanaka
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assesse
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	None None None	36 months
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: \$	September 26, 2023	
Your Name:_	ne: Masafumi Oda	
Manuscript 1	pt Title: Comparison of the distribution of the Bartholin and/or Rivinus sal	<u>ivary ducts assessed</u>
with MR-si	R-sialography in patients with ranula and in healthy subjects	
Manuscript r	pt number (if known): QIMS-23-947-R1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 2023
Your Name: Shinobu Matsumoto-Takeda
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 2023
Your Name: Manabu Habu
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Your Name: Shun Nishimura
Total Parameter -
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	None			
	testimony				
	·				
7	Support for attending meetings and/or travel	None			
8	Patents planned, issued or	None			
	pending				
9	Participation on a Data	None			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role				
10	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	None			
12	Receipt of equipment,	None			
	materials, drugs, medical				
	writing, gifts or other services				
13	Other financial or non-	None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
7	The authors have no financial conflicts of interest disclose concerning the study.				

Date: Septer	nber 26, 2023			
Your Name: Os	amu Takahashi			
Manuscript Title:	Comparison of the distr	ibution of the Bar	tholin and/or Rivinus	s salivary ducts assessed
with MR-sialogr	aphy in patients with ran	ıla and in healthy	subjects	-
Manuscript number	r (if known):_QIMS-23-947-F	1		
-	· —			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 2023
Your Name: Ikuko Nishida
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assesse
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None				
	lectures, presentations, speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	None				
	testimony					
_						
7	Support for attending meetings and/or travel	None				
8	Patents planned, issued or pending	None				
9	Participation on a Data	None				
	Safety Monitoring Board or Advisory Board					
10	Leadership or fiduciary role	Director of Japanese				
	in other board, society,	Society of Pediatric				
	committee or advocacy	Dentistry				
	group, paid or unpaid					
11	Stock or stock options	None				
	·					
12	Receipt of equipment,	None				
	materials, drugs, medical writing, gifts or other					
	services					
13	Other financial or non-	None				
	financial interests					
Dlos	Disconsissing the characteristic of interest in the faller in the faller.					
FIE	Please summarize the above conflict of interest in the following box:					
Г	The authors have no financial conflicts of interest disclose concerning the study.					

Date: September 26, 2023
Your Name: Hiroki Tsurushima
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

You Mar with Mar In th	n MR-sialography in pations of the machine in the machine interest of transparency, ted to the content of your necessity.	on of the distribution of ients with ranula and in QIMS-23-947-R1 we ask you to disclose all r nanuscript. "Related" mean	the Bartholin and/or Rivinus salivary ducts assessed healthy subjects elationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment	ssed		
to t	ansparency and does not no	ecessarily indicate a bias. I	f you are in doubt about whether to list a			
rela	tionship/activity/interest, it	is preferable that you do s	60.			
	The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .					
to the	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare a tion is not mentioned in th port for the work reported the past 36 months.	in this manuscript without time limit. For all other iter	е		
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed) Time frame: Since the initial	planning of the work			
1	All support for the present	None	planting of the work			
-	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					

	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 2023
Your Name: Jumpei Tanaka
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, None None None None None None None				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, Safety Monitoring Board or Advisory Board None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society,				
Advisory Board 10 Leadership or fiduciary role in other board, society,				
10 Leadership or fiduciary roleNoneNone				
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsNone				
12 Receipt of equipment,NoneNone				
writing, gifts or other services				
13 Other financial or non- financial interestsNone				
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 2023	
Your Name: Susumu Nishina	
Manuscript Title: Comparison of the distribution of the Bartholin and	or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects	
Manuscript number (if known): QIMS-23-947-R1	
In the interest of transparency, we ask you to disclose all relationships/activiti	os/interests listed helevy that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	None		
	testimony			
	·			
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role			
10	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment,	None		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	None		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
7	The authors have no financial conflicts of interest disclose concerning the study.			

Date: September 26, 2023
Your Name: Daigo Yoshiga
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None		
	educational events			
6	Payment for expert testimony	None		_
	,			_
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	None		
	pending			_
9	Participation on a Data	None		
	Safety Monitoring Board or			Ī
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	None		
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment,	None		
	materials, drugs, medical			_
	writing, gifts or other services			
13	Other financial or non-	None		
	financial interests			
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 2023
Your Name: Masaaki Sasaguri
Manuscript Title: Comparison of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in patients with ranula and in healthy subjects
Manuscript number (if known): QIMS-23-947-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None		
	educational events			
6	Payment for expert testimony	None		_
	,			_
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	None		
	pending			_
9	Participation on a Data	None		
	Safety Monitoring Board or			Ī
	Advisory Board			
10	Leadership or fiduciary role in other board, society,	None		
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment,	None		
	materials, drugs, medical			_
	writing, gifts or other services			
13	Other financial or non-	None		
	financial interests			
Please summarize the above conflict of interest in the following box: The authors have no financial conflicts of interest disclose concerning the study.				

Date: September 26, 202	23
Your Name: Yasuhiro Mor	imoto
Manuscript Title: Comparis	son of the distribution of the Bartholin and/or Rivinus salivary ducts assessed
with MR-sialography in pat	tients with ranula and in healthy subjects
Manuscript number (if known)	:_QIMS-23-947-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
	testimony			
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
10	Advisory Board	5 6.1		
10	Leadership or fiduciary role	Executive director of the		
	in other board, society,	Japanese Society for Oral		
	committee or advocacy	and Maxillofacial		
	group, paid or unpaid	Radiology		
		Director of the Japanese		
		Society of Oral Diagnosis/Oral Medicine		
		Diagnosis/Oral Medicine		
11	Stock or stock options	None		
11	Stock of Stock options	None		
12	Receipt of equipment,	None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	None		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
_				
	The authors have no financial conflicts of interest disclose concerning the study.			